MedAI Verdict
Decision support

Clinical Decision Support

RhythmX AI logo

RhythmX AI

by RhythmX AI

Last verified

Precision care platform that surfaces next-best actions and risks inside the EHR at the point of care for physicians and health systems.

Visit RhythmX AI (opens in new tab)Read our methodology

At a glance

Pricing
No public price. Demo only.
HIPAA
Not disclosed
SOC 2
Not disclosed
EHRs
—
Founded
—
On this page

Independent score  ·  By our public rubric

5/100Tracked

Not rated: too little independent evidence yet.

How it’s computed →
  • Regulatory & Compliance
    0/22

    No FDA clearance listed

  • Clinical Integration
    0/11.6

    No EHR integrations listed

  • Evidence Strength
    0/30

    No peer-reviewed coverage

  • Vendor & Market
    3/18

    Seed-stage or unfunded

  • Sentiment & Transparency
    1.3/2.5

    Pricing on request, no public amounts

▸ Show all 11 dimensions

Regulatory & Compliance

  • FDA clearance0/12

    No FDA clearance listed

  • HIPAA / SOC2 / BAA0/10

    No public HIPAA/SOC2/BAA attestation

Clinical Integration

  • EHR integrations (count)0/6

    No EHR integrations listed

  • Top-3 EHR coverage (Epic / Oracle / Athena)0/5

    None of the top-3 EHRs covered

  • Bidirectional write-back0/1

    No bidirectional write-back documented

Evidence Strength

  • Peer-reviewed papers0/21

    No peer-reviewed coverage

  • RCT / meta-analysis / systematic review0/9

    No RCT, meta-analysis, or systematic review

Vendor & Market

  • Funding & adoption signal3/12

    Seed-stage or unfunded

  • Years in market0/6

    Founded year not recorded

Sentiment & Transparency

  • Pricing transparency1/3

    Pricing on request, no public amounts

Scored November 2, 2026 · Public scoring method v1.2.0

Precision care platform that surfaces next-best actions and risks inside the EHR at the point of care for physicians and health systems.

No public price. Demo only.

Evidence record

FDA decisions

No FDA decision cited in our research as of November 2, 2026.

Verification
  • Score computed November 2, 2026, method 1.2.0
  • Review written November 2, 2026
Cite this record

MedAI Verdict, RhythmX AI record, https://medaiverdict.com/tools/rhythmx-ai, version November 2, 2026

Change history
View every change to this record

Bottom line

RhythmX AI calls itself "the world's first native generative AI precision care platform for doctors", delivering personalized interventions inside EHR workflows. It is owned by SAI Group and aimed at physicians and health systems that want recommendations at the point of care. A buyer who must see an EHR list, a customer reference or a security attestation before a first meeting should look elsewhere.

What does the platform say it does?

The vendor describes risk profiling AI, a Patient360 AI engine, disease progression trajectories and recommendations for labs, imaging, social care, follow-ups and medications. A workflow layer is meant to close quality gaps and route patients to the right clinician. It is built on Eureka, a generative AI platform from SAI Group, and the about page calls the company "An AI-native healthcare company".

The homepage carries clinician testimonials chosen by the vendor. One, from Dr. Anish Shah, credits the platform with reducing cognitive burden and says the recommendations are "all integrated into the EHR workflows". A testimonial also cites an outside study on primary care patient loads, which the page does not source.

Who stands behind it?

The about page says RhythmX AI is owned by SAI Group. SAI Group's principal owner and the company's chairman, Dr. Romesh Wadhwani, "has committed up to $1 billion in equity capital" across portfolio companies, and no RhythmX-specific amount is given. ConcertAI, a sister company, is named on the site.

Deepthi Bathina is founder and CEO. Jason Williams is operating partner, Chris Heddon general manager, Tim Kostner chief revenue officer and Erika Green, MD, director of clinical informatics. The advisory board includes executives at Sentara Health, Prime Healthcare, Mass General Brigham, Geisinger and Microsoft. Headquarters, founding year and legal entity are not stated.

What is not stated?

No customer count or EHR is given, and the vendor cites no HIPAA statement or security audit. It makes no FDA statement, and no RhythmX or Rhythm X device appears among 510(k) clearances, so whether it positions the platform as exempt decision support is unstated. PubMed returns 16 hits for "RhythmX", all unrelated cohort and hypertension papers.

The site lists no price and offers a demo.

The verdict

RhythmX AI suits a health system that can judge a Patient360 recommendation engine from a demo. Its pitch is next-best actions and risks surfaced inside the EHR at the point of care, and a demo is the way in.

Editorial review last generated November 2, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.

What it costs

All tiers are custom-quoted. The vendor does not publish per-provider list pricing.

TierMonthlyAnnualNotes
EnterpriseNot statedNot statedNo public price. Demo only.

Source: vendor pricing page. Last checked November 2, 2026.

Other decision support

See the full decision support ranking